Navigation Links
Dismantling pancreas cancer's armor
Date:2/20/2014

SEATTLE Pancreas cancer is notoriously impervious to treatment and resists both chemotherapy and radiotherapy. It has also been thought to provide few targets for immune cells, allowing tumors to grow unchecked. But new research from Fred Hutchinson Cancer Research Center shows that pancreas cancer "veils" itself from the immune system by recruiting specialized immune suppressor cells. The research team also found that removing these cells quickly triggers a spontaneous anti-tumor immune response.

The findings, published Feb. 20 in Gut, give hope for future immunotherapy strategies against this deadly and aggressive cancer.

"The take-home message is that there is a latent immune response against pancreas cancer that can be expressed if we remove its obstacles," said Sunil Hingorani, M.D., Ph.D., an associate member of the Clinical Research Division at Fred Hutch, who led the study. "Removing the suppressor cells creates a context that could enable an adoptive immune cell therapy against pancreas cancer."

An almost uniformly deadly cancer

Pancreas cancer is almost uniformly deadly. About 45,000 people are diagnosed with the disease in the U.S. each year. "The mortality rate is essentially the same as the incidence rate," Hingorani noted. Pancreas cancer "doesn't obey the rules" established for other solid tumors, he said: It metastasizes early, resists traditional treatment, and survives quite well on a diminished blood supply.

The tumor builds a fibrous wall around itself which exerts so much pressure that blood vessels entering the tumor are constricted, which also prevents chemotherapy from entering. In addition, scientists have historically had difficulty stimulating a therapeutic immune response against pancreas tumors because they have identified few molecular targets on which to focus the immune attack.

But as the new findings in a mouse model show, pancreas tumors fly under the radar not because they lack targets for the immune system, but because they recruit suppressor cells that keep immune cells at bay. When these immune suppressor cells are removed, helpful immune cells spontaneously move into the tumor and begin their attack.

Activating a T-cell response against the cancer

Pancreas cancer is nearly always diagnosed at very late stages, which has made its development hard to study. To gain insight into these aggressive tumors, Hingorani's team pioneered the development of a genetic mouse model of pancreas cancer. Previous work in the model led to their discovery of an enzyme that can make pancreas tumors more permeable to chemotherapy. The group turned again to this model to learn more about how pancreas tumors interact with the immune system.

From their earlier work, Hingorani's team knew that several different types of immunosuppressive cells infiltrate pancreas tumors. Together with immunologist Philip Greenberg, M.D., a member of Fred Hutch's Clinical Research Division, they have begun studying ways to target these inhibitory cells. As Ingunn Stromnes, Ph.D., the postdoctoral researcher co-mentored by Hingorani and Greenberg who spearheaded this latest study, watched pancreas tumors develop in mice, she saw that one cell type stood out. Descended from bone marrow cells and dubbed granulocyte-myeloid-derived suppressor cells (Gr-MDSCs), these cells jumped in number as pancreas tumors turned invasive. Stromnes discovered the pancreas tumors were orchestrating the accumulation of these suppressor cells by releasing a protein known as granulocyte macrophage colony-stimulating factor (GM-CSF), which attracted the Gr-MDSCs.

Strikingly, the Gr-MDSCs actively worked against T cells, a class of immune cell central to many immunotherapy strategies. T cells are often harnessed to fight tumors because they can recognize very specific molecules and destroy any cells expressing those molecules. But Gr-MDSCs prevented T cells from dividing and even induced their death.

Stromnes found this effect could be reversed, however, and the T-cell response activated, by depleting Gr-MDSCs. When she did so, she saw evidence not only that the T cells could now enter the tumors, but also that the tumors showed evidence of the type of cellular damage the T cells are designed to mete out.

"The findings are important because they show that the tumor microenvironment itself, and in particular a specific subset of cells in the tumor, is preventing T cells from trafficking to the tumor and mounting a response," Stromnes said. Importantly, humans also possess cells very similar to Gr-MDSCs, which strengthens the case that similar strategies could impact human pancreas cancer. Additionally, the damage wreaked on Gr-MDSC-depleted tumors appeared to release some of the pressure inside the tumor, allowing crushed blood vessels to open again and providing a potential avenue for chemotherapy.

'We want to put as big a hurt on pancreas cancer as possible'

The results are a backbone on which the team can begin designing a multipronged approach to pancreas cancer therapies, Stromnes noted. The findings show that a T-cell-based therapy alone may not be enough. Researchers must also take into account pancreas cancer's immunosuppressive strategies. "We're trying to get the helpful immune cells into the tumors, and our results show that to do that, we need to get rid of these inhibitory cells the tumors have co-opted," she said.

The team is now working to develop a T-cell therapy to take advantage of their new findings. They plan to test their Gr-MDSC strategy combined with immunotherapy as well as chemotherapy to devise the strongest possible treatment for pancreas cancer.

"Our goal is not incremental advances," Hingorani said. "We want to put as big a hurt on pancreas cancer as possible."


'/>"/>

Contact: Kristen Woodward
media@fredhutch.org
206-667-2210
Fred Hutchinson Cancer Research Center
Source:Eurekalert  

Related medicine news :

1. UCLA study finds link between high-fat, high-calorie diet and pancreas cancer
2. EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma
3. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
4. Mini-Organ Would Mimic Pancreas to Treat Type 1 Diabetes
5. Artificial Pancreas Worked Overnight on Kids With Type 1 Diabetes
6. Artificial pancreas: The way of the future for treating type 1 diabetes
7. Pancreas stem cell discovery may lead to new diabetes treatments
8. A leap forward in the quest to develop an artificial pancreas
9. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
10. Statins Wont Hurt, Might Even Help, Your Pancreas: Study
11. New marker for identifying precursors to insulin-producing cells in pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dismantling pancreas cancer's armor
(Date:2/22/2017)... ... February 22, 2017 , ... A product of digesting a micronutrient ... a heart-protective benefit from eating soy foods, while others do not, a University of ... able to produce equol—a substance made by some types of “good” gut bacteria when ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued to steadily ... the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, APOP also ... the benefits of corn and grains, value of raw and organic diets, and the ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a recent ... the patient context (age, illness and life choices) should be dissociated from medical ... In addition, all too often, studies regarding health system performance in ...
(Date:2/21/2017)... Okla. (PRWEB) , ... February 21, 2017 , ... ... new Choctaw Nation Regional Medical Clinic in Durant, Oklahoma, on Feb. 21. , ... by clinic tours for community members, clinic employees, the construction team and tribal ...
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have ... related to surgery, treatment, therapy and management. Regular exercise in proper environments has ... life despite their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 Research and Markets has ... Market (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, By ... ... is forecasted to grow at a CAGR of 5.33% during 2016-2021 ... of infectious diseases along with surging demand of digital thermometer. Apart ...
(Date:2/22/2017)... -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company ... field of urology, today announced the expansion of its ... from 35 currently, a 20% increase in the company,s ... is being driven by the increasing growth of Natesto, ... acceptance of Natesto,s unique product profile and clinical benefits. ...
(Date:2/22/2017)...  CVS Pharmacy is the first national retail pharmacy ... (PHO), the primary source of artificial trans fats in ... products. The retailer now offers over 600 exclusive snack ... fats. This comes a year and a half ahead of ... for processed foods to be reformulated without artificial trans ...
Breaking Medicine Technology: